Financials in USD. Standardized financial statements.
A compact view of how Braxia Scientific Corp. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Revenue? | $1.88M | $1.49M | $1.01M | $212 |
| Revenue Growth? | +26.7% | +47.5% | +475547.2% | 0.0% |
| Cost of Revenue? | $1.71M | $4.77M | $3.90M | $9,158 |
| Gross Profit? | $171,743 | -$3.28M | -$2.89M | -$8,946 |
| Gross Margin? | +9.1% | -220.7% | -286.7% | -4219.8% |
| Operating Expenses? | $7.65M | $7.38M | $10.69M | $163,520 |
| Operating Income? | -$7.48M | -$7.16M | -$10.54M | -$172,470 |
| EBITDA? | -$12.70M | -$7.14M | -$88.81M | -$3.30M |
| Income Before Tax | -$13.29M | -$12.18M | -$88.45M | -$172,723 |
| Income Tax Expense | -$145,882 | -$45,267 | $376,306 | $0 |
| Net Income? | -$13.14M | -$12.13M | -$88.83M | -$172,723 |
| EPS? | $-0.06 | $-0.07 | $-0.56 | $-0.00 |
| Diluted EPS? | $-0.06 | $-0.07 | $-0.56 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality